首页AutophagyHistone Methyltransferase
Histone Methyltransferase
T0174 Cyproheptadine hydrochloride Cyproheptadine hydrochloride sesquihydrate, an antihistamine, is an antagonist of serotonin and histamine2.
T10427 AZ505 ditrifluoroacetate AZ505 ditrifluoroacetate is an effective and selective SMYD2 inhibitor (IC50: 0.12 μM).
T10840L CM-579 CM-579 is a dual inhibitor of G9a and DNMT( IC50:16 nM, 32 nM for G9a and DNMT). It has potent in vitro cellular activity in a wide range of cancer cells.
T10882 CPUY074020 CPUY074020 is a potent and orally bioavailable inhibitor of histone methyltransferase G9a (IC50: 2.18 μM) with anti-proliferative activity.
T11081 Dot1L-IN-1 The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.
T11082 Dot1L-IN-2 Dot1l-in-2 is an effective, selective and oral bioutilization inhibitor of histone methyltransferase Dot1L, with IC50 and Ki of 0.4 nM and 0.08 nM, respectively.
T11083 Dot1L-IN-4 Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 SPA DOT1L of 0.11 nM.
T11084 Dot1L-IN-5 Dot1L-IN-5 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 SPA DOT1L of 0.17 nM.
T11131 DW14800 DW14800 reduces H4R3me2s levels and enhances the transcription of HNF4α, but does not alter PRMT5 expression. Anti-cancer activity.DW14800 is a protein arginine methyltransferase
T11185 EML741 EML741 also inhibits DNMT1 (IC50, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated. E
T11436 GNA002 GNA002 is a highly potent, specific, and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor (IC50: 1.1 μM).
T11486 GSK2807 Trifluoroacetate GSK2807 Trifluoroacetate is a selective and SAM-competitive inhibitor of SMYD3 (Ki: 14 nM; IC50: 130 nM).
T11500 GSK3368715 GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s: 3.1 nM (PRMT1), 48
T11500L GSK3368715 dihydrochloride GSK3368715 dihydrochloride is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s: 3.
T12428 PF-06726304 acetate PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity.
T12428L PF-06726304 PF-06726304 shows robust antitumor growth activity. PF-06726304 is an effective and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 (Kis: 0.7 and 3.0
T12541 PRMT5-IN-1 PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).
T12939 SMYD2-IN-1 SMYD2-IN-1 is an inhibitor of SMYD2 (IC50 of 4.45 nM).
T12940 SMYD3-IN-1 SMYD3-IN-1 is an irreversible and selective SMYD3 (SET and MYND domain containing 3) inhibitor(IC50 of 11.7 nM).
T12943 SNDX-5613 SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute
T13279 Valemetostat tosylate Valemetostat tosylate is a dual inhibitor of EZH1/2 and used in the research of relapsed/refractory peripheral T-cell lymphoma.
T13780 MS1943 MS1943 is a orally bioavailable EZH2 selective degrader(IC50 of 120 nM).
T15080 DC-05 DC-05 is an inhibitor of DNA methyltransferase 1 (DNMT1) (IC50 and a Kd: 10.3 μM and 1.09 μM, respectively).
T15194 EBI-2511 EBI-2511 is a highly potent and orally active inhibitor of EZH2 (IC50: 6 nM in Pfeffiera cell lines).
T15240 Tazemetostat trihydrochloride Tazemetostat trihydrochloride is a selective and orally available inhibitor of EZH2 (IC50: 4 nM for rat EZH2). It inhibits the activity of human PRC2-containing wild-type EZH2 (Ki:
T15624 JNJ-64619178 JNJ-64619178 is a selective, orally active, and pseudo-irreversible inhibitor of protein arginine methyltransferase 5 (IC50: 0.14 nM). It has effective activity In lung cancer.
T15775 Lotilaner Lotilaner is a parasiticide. It is used as a potent non-competitive antagonist of insects GABACl receptors (IC50 of 23.84 nM for Drosophila melanogaster GABA receptor). It also has
T16072 MI-538 MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM).
T16435 PBIT PBIT inhibits JARID1B histone demethylase (IC50 of about 3 μM). PBIT also inhibits JARID1A and JARID1C (IC50s of 6 μM and 4.9 μM, respectively). PBIT is a specific inhibitor of
T16577 PRMT5-IN-2 PRMT5-IN-2 is an inhibitor of protein arginine methyltransferase 5.
T17002 Tazemetostat hydrobromide Tazemetostat hydrobromide is a potent and selective EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-ty
T17203 UNC0224 UNC0224 is inactive against SET7/9, SET8/PreSET7, PRMT3, and JMJD2E. UNC0224 is a potent and selective histone methyltransferase G9a inhibitor (Ki: 2.6 nM, an IC50 of 15 nM, and a
T17204 UNC0321 UNC0321 is inactive against SET7/9, SET8/PreSET7, PRMT3, and JMJD2E. UNC0321 is an effective and selective histone methyltransferase G9a inhibitor (Ki: 63 pM) and (assay-dependent
T1775 GSK503 GSK-503, a potent EZH2 inhibitor, has potential antitumor activity.
T1788 EPZ6438 Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase EZH2, with potential antineoplastic
T1841 UNC0379 UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
T1868 JIB04 JIB-04 is a pan-selective Jumonji histone demethylase inhibitor.
T1905 EPZ005687 EPZ005687 is a potent and selective inhibitor of EZH2.
T1923 BRD4770 BRD4770 is a histone methyltransferase G9a inhibitor and induces cell senescence.
T1959 BIX 01294 Trihydrochloride BIX01294 is an inhibitor of G9a histone methyltransferase.In a cell-free assay, the IC50=2.7 μM for G9a histone methyltransferase.
T1987 PFI2 PFI-2 is an effective, specific and cell-active lysine methyltransferase SETD7 inhibitor (Ki/IC50: 0.33/2 nM), 1000-fold selectivity over other methyltransferases and other non-epi
T2079 GSK126 GSK126 is a excellently specific EZH2 methyltransferase inhibitor ( IC50=9.9 nM).
T2097 C7280948 C-7280948 is a PRMT1 inhibitor.
T22325 EPZ020411 2HCl EPZ020411 is a selective and potent small molecule PRMT6 inhibitor with an IC50 value of 10 nM.
T22342 GSK3368715 3HCl GSK3368715, a potent inhibitor of type I protein arginine methyltransferases (PRMT), could inhibit PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81 nM.
T2352 AMI1 AMI-1 is an effective and selective Histone Methyltransferase (HMT) inhibitor (IC50: 3.0/8.8 μM, for yeast Hmt1p, and human PRMT1).
T2354 UNC0631 UNC0631 is a effectvie histone methyltransferase G9a inhibitor (IC50=4 nM).
T2435 EPZ011989 EPZ011989 is a effective, specific orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 Y646 and EZH2 wt; 15-fold selectivity over EZH1 and >3000-fold selectivity over other
T2649 MI2 MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.
T3057 UNC1999 UNC1999 is a orally bioavailable, effective and specific inhibitor of EZH2 (IC50=2 nM) and EZH1 (IC50=45).
T3081 EPZ004777 EPZ004777 is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM.
T3081L EPZ004777 HCl EPZ004777 hydrochloride is a potent, selective DOT1L inhibitor with IC50 of 0.4 nM.
T3082 SGC0946 SGC0946 is a highly effective and specific DOT1L methyltransferase inhibitor (IC50: 0.3 nM); selectively kill mixed lineage leukemia cells.
T3084 SGC707 SGC707 is a potent, selective, and cell-active allosteric inhibitor of PRMT3.
T3099 Pinometostat EPZ5676 has been used in trials studying the treatment of Leukemia, Acute Leukemias, Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Acute Lymphocytic Leukemia, among others.
T3257 UNC0638 UNC0638 is an inhibitor of β-protein lysine methyltransferases G9a(IC50<15 nM) and GLP(IC50=19 nM) with excellent potency and selectivity over a wide range of epigenetic and non-e
T3458 EED226 EED226 is a potent, selective, and orally bioavailable embryonic ectoderm development (EED) inhibitor with an IC50 of 22 nM.
T3624 A366 Potent and selective G9a/GLP histone lysine methyltransferase inhibitor (IC50 = 3.3 nM). Exhibits >1000-fold selectivity for G9a/GLP over 21 other methyltransferases. Decreases le
T4013 SGC2085 HCl SGC2085 is a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) Inhibitor with an IC50 of 50 nM and more than undred-fold selectivity over other PRMTs
T4021 UNC3866 UNC3866 is a potent antagonist of the CBX7-H3 interaction as determined by AlphaScreen.
T4021L UNC3866 TFA(1872382-47-2 free base) UNC3866 TFA is a potent antagonist of the CBX7-H3 interaction as determined by AlphaScreen.
T4166 UNC0642 UNC0642 is an effective and specific G9a/GLP inhibitor (IC50< 2.5 nM).
T4314 EPZ020411 EPZ020411 is a specific and effective inhibitor of PRMT6 (IC50=10 nM).
T4334 EPZ020411 2HCl (1700663-41-7(free base)) EPZ020411 is an effective and specific small molecule PRMT6 inhibitor (IC50=10 nM).
T4343 A196 A-196 is a potent and selective inhibitor of SUV420 h1 and SUV420 h2 with IC50 values of 0.025 and 0.144 μM, respectively; more than 100-fold selective over other histone methyltr
T4378 MS049 MS 049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC 50 of 34 nM and 43 nM, respectively.
T4393 MS049 2HCl (1502816-23-0(free base)) MS049 is a potent and selective inhibitor of PRMT4 (IC50 = 34 nM) and PRMT6 (IC50 = 43 nM). It is less active against additional type I PRMTs (IC50s = >130, >220, and 1.6 μM for P
T4583 (R)-PFI-2 hydrochloride PFI-2 hydrochloride is a potent, highly selective, and cell-active inhibitor of the methyltransferase activity of SETD7 (IC50: 2 nM), 500 fold active than (S)-PFI-2.
T5322 BCI121 BCI-121 is a substrate-competitive SMYD3 inhibitor that inhibits the proliferation of the cancer cell.
T5605 EZM 2302 EZM2302 is a selective, and orally available arginine methyltransferase CARM1 inhibitor (IC50: 6 nM).
T5745 GSK3326595 GSK3326595 is an inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50:6.2 nM.).
T6059 GSK343 GSK343, a specific and effective EZH2 inhibitor (IC50=4 nM), exhibits 60 fold specificity activity against EZH1, and >1000 fold specificity activity against other histone methyltra
T6076 EPZ015666 EPZ015666 is an orally available inhibitor of PRMT5 enzymatic activity.
T6333 MM102 MM-102 is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM.
T6484 EI1 EI1 is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
T6790 BMS911543 BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.
T6809 CPI169 CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
T6853 GSK591 GSK591, Alternative Names are EPZ015866, GSK3203591, is a potent selective inhibitor of the arginine methyltransferase PRMT5 (IC50=11 nM).
T6857 HLCL-61 hydrochloride HLCL-61 hydrochloride is a potent and selective PRMT5 inhibitor for the treatment of acute myeloid leukemia.
T6879 LLY507 LLY-507 is an effective, cell-active, and specific inhibitor of protein-lysine Methyltransferase SMYD2.
T6900 MS023 MS023 is a potent, selective, and cell-active Type I PRMT inhibitor with IC50 of 30 nM, 119 nM, 83 nM, 4 nM, and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.
T7089 SGC2085 SGC2085 is an effective and selective coactivator-associated arginine methyltransferase 1 (CARM1) inhibitor (IC50: 50 nM).
T7157 XY1 XY1 is a very close analogue of SGC707 (a potent, selective, and non-competitive inhibitor of PRMT3 with IC50 of 31 nM),  It is intended to be used as a negative control for SGC7
T7305 JQEZ5 JQEZ5 is an inhibitor of EZH2 lysine methyltransferase (IC50 = 11.1 nM).
T7378 BRD9539 BRD9539 is an inhibitor of euchromatin histone methyltransferase 2 (EHMT2), also known as G9a, with an IC50 value of 6.3 µM
T7403 BAY-598 BAY-598 is a selective inhibitor of SMYD2 with IC50 values of 27 nM.
T7697 BIX-01294 BIX-01294 is an G9a Histone Methyltransferase inhibitor(IC50 : 1.9 μM).
T8201 Gambogenic acid Gambogenic acid is a natural product,is an effective inhibitor of EZH2,with anticancer activity.
T8510 CPI-1205 CPI-1205 is a highly potent and selective inhibitor of EZH2(IC50 : 0.002 μM, EC50 : 0.032 μM) .
T8768 MM-102 TFA MM-102 TFA is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM. MM-102 compound prevents the interaction between mixed lineage leukemia 1 (MLL1) and WD Trp-Asp repe
T8838 CCI 007 CCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485
T8881 Dot1L-IN-4 Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor.
TN5096 Tanshindiol B Tanshindiol B possesses a unique anti-cancer activity whose mechanism involves the inhibition of EZH2 activity and would provide chemically valuable information for designing a new
TN5097 Tanshindiol C Tanshindiol C protects macrophages from oxLDL induced foam cell formation via activation of Prdx1/ABCA1 signaling and that Prdx1 may be a novel target for therapeutic intervention
TQ0058 MI-463 MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM).
TQ0069 MI-503 MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction.
TQ0100 AZ505 AZ505 is an effective and specific SMYD2 inhibitor (IC50: 0.12 μM).
TQ0232 UNC 0646 UNC 0646 is a potent and selective inhibitor of the homologous protein lysine methyltransferases, G9a and GLP (IC50s: 6 nM/15 nM for G9a/GLP). UNC0646 potently blocks G9a/GLP methy
TQ0263 EPZ031686 EPZ031686 is a selective and orally available SMYD3 inhibitor (IC50: 3 nM).
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。